---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000514"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:56:09.310137+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed

## Summary
- Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.
- EsoGuard revenue of $1.2M for Q4; GAAP net loss $11.5M ($0.20/share); non-GAAP loss $10.9M ($0.19/share).
- Cash and equivalents $22.4M at Dec 31, 2024; pro forma ~$36.9M after Q1 2025 common stock financing.
- Secured first commercial coverage from Highmark and first state biomarker agreement with Blue Cross Blue Shield of RI.
- Completed $22M convertible debt refinancing and $15.3M stock financing, net proceeds $32.8M, extending cash runway.

## SEC filing metadata
- accession: 0001641172-25-000514
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000164117225000514/0001641172-25-000514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000164117225000514/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000514
- JSON: https://secwatch.observer/filing/0001641172-25-000514.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.